How do you guys feel about IVOB? Penny stock now? But….?
But they just hit the news!
INVO Bioscience, Inc. (OTCBB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announces that the US National Institute of Health (NIH) and the World Health Organization (WHO) has approved a 100 patient study being conducted by Galaxy IVF in three INVO centers in Pakistan. The purpose of the study is to evaluate a low cost stimulation protocol combined with INVO to make an IVF affordable procedure available across the large infertile/sub-fertile population. The study will use a minimum ovarian stimulation protocol with the primary endpoint being number of follicles obtained and the fertilization rate. The secondary endpoints will be pregnancy rate and cost of treatment.
Recruitment has begun for the study and Dr. Ranoux will be attending the first INVO cycles at each of the clinical sites.
Galaxy IVF has discontinued the original study started in the IVF center in Lahore because of major protocol violations by the site. The new study will be performed in INVO centers that have been trained and have already performed INVO cycles per the protocols outlined in the INVOcell Instructions for Use.
This additional data will support the widespread acceptance of the INVO in the Middle East.
The approved protocol can be reviewed at the NIH site link:
http://www.clinicaltrials.gov/ct2/show/NCT01058252?term=Galaxy+Pharma&rank=1
or the WHO site link:
http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT01058252
About INVO Bioscience
INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company’s lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman’s vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
This is a junk penny stock. Stand back for a moment and look at the facts rather than the company’s own "promises", they currently trade at a price per share roughly equal to the amount of money per share that they have lost per share in the last twelve months….does that sound like they are running a "sound business" to you? Honestly?
Imagine that instead of making $59B, Microsoft had actually lost $28/share (or ~$311,000,000,000) over the last year, proportionately that would be the same thing, would you consider that a "buy"?
INVO is just another scam….